Phase Holographic Imaging PHI AB
Phase Holographic Imaging PHI AB
10/28/2024 | Press release | Distributed by Public on 10/28/2024 07:09
Phase Holographic: PHI secures a loan from Altium SA
Press release from Companies
Publicerat: 2024-10-28 14:08:34
Phase Holographic Imaging PHI AB: PHI secures a loan from Altium SA
Phase Holographic Imaging PHI AB ("PHI") announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
Altium SA has provided PHI with a loan of SEK 7 million, granting PHI funds to repay a previous loan raised from Bizcap AB earlier this year. The loan has an interest rate of 1.5 percent per month, and a maturity date on the 30th of June 2025. PHI can repay the loan and interest at any time before the maturity date.
The Board of Directors of PHI and Altium SA, as the main shareholder, are also in discussions regarding alternatives for long-term financing of PHI. These discussions also include the convertible loan which in October last year was acquired by Altium SA from Fenja Capital (previously Formue Nord).
This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-10-2024 14:08 CET.
For additional information, please contact:
Lisa Bodily
E-mail: [email protected]
Web: www.phiab.com - Live cell imaging & analysis
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.